CardioNet Awarded its 15th U.S. Patent.

Newest Patent for Biological Signal Management

CONSHOHOCKEN, Pa. -- CardioNet, Inc. (NASDAQ: BEAT) announced today that the U.S. Patent and Trademark office has granted patent number 7,587,237 ("Biological Signal Management") to CardioNet. The patent includes certain systems and techniques utilized by the Company's Mobile Cardiac Outpatient Telemetry[TM] (MCOT[TM]) system that automatically processes complex physiological information to make it useful for clinical decisions. This is the 15th U.S. Patent that has been issued to CardioNet.

Randy Thurman, CardioNet Chairman, President and CEO, commented, "A key to success in delivering wireless medicine is rooted in our ability to distill the wide variety of information collected from sensors on the body and make that data useful for clinicians or other healthcare providers. With MCOT[TM], we provide electrocardiogram and trended heart rate data to physicians in order for them to make clinically relevant decisions. The issuance of this patent demonstrates our continued focus on innovation for applications in wireless medicine. Establishing and defending our extensive patent portfolio is key to our long-term strategy. This newly issued patent reinforces CardioNet's position as the pioneer and technology leader in mobile cardiac outpatient telemetry."

The issued patent abstract states: Systems and techniques for managing biological signals. In one implementation, a method includes receiving a cardiac biological signal that includes information describing events, determining a merit of each event based on one or more of a severity of a cardiac condition associated with the event and a quality of the event, and handling a subset of the events that meet a merit criterion. The subset can be handled for medical purposes.

About CardioNet

CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health. CardioNet's initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient Telemetry[TM] (MCOT[TM]). More information can be found at http://www.cardionet.com.

Forward Looking Statements

This press release includes certain forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in the Company's future. These statements may be identified by words such as "expect," "anticipate," "estimate," "intend," "plan," "believe," "promises" and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, changes to reimbursement levels for our products, the continued consolidation of payors, acceptance of our new products and services and patent protection and litigation. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.